BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 08, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Provenge sipuleucel-T: Updated Phase III data

Updated data from the double-blind, North American Phase III IMPACT trial (D9902B) in 512 men with metastatic AIPC showed that Provenge continued to extend median OS by 4.1 months compared with placebo after a median follow-up of 36.5 months (p=0.017). Provenge...

Read the full 184 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >